Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of dronabinol oral drops (BX-1) for symptomatic relief of multiple sclerosis spasticity
2018-000001-23Phase 3Completed
- Sponsor
- Bionorica
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing BX-1 / dronabinol with Placebo (2 arms). Primary endpoint: NRS-S responder analysis. Started Aug 2018; status: completed.
02
Drugs
dronabinol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-000001-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000001-23.